HSK16149 20mg-40mg BID
DrugOral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
NCT Number: NCT06422117
To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
Placebo, oral, 2 capsules twice daily
Time frame: week12
Changes in mean pain intensity (ADPS) at week 12 between HSK16149 and placebo were compared from baseline;The pain NRS score divides a straight line into 10 segments, with 0 to 10 indicating pain (a total of 11 points), 0 indicating no pain, and 10 indicating the most intense pain. The pain NRS scores of the past 7 days were collected and the average value was used as the ADPS score.
Haisco Pharmaceutical Group Co., Ltd.
Industry
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate to Severe Central Neuropathic Pain in China
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06723561
Central Nervous System Diseases, Central Neuropathic Pain
Milwaukee, Wisconsin, United States
View Trial DetailsNCT02218203
Agnosia, Allodynia
Boston, Massachusetts, United States
View Trial DetailsNCT01435798
Agnosia, Allodynia
Boston, Massachusetts, United States
View Trial DetailsNCT06978764
Central Neuropathic Pain
São Paulo, Brazil
View Trial Details